Brian Baranick serves as the Executive Vice President and General Manager of Precision Oncology at Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests. In his role, Baranick oversees the development and commercialization of the company's precision oncology products, which aim to provide personalized treatment options for cancer patients based on their unique genetic profiles. His leadership has been instrumental in driving the growth and success of Exact Sciences' precision oncology division. Prior to joining Exact Sciences, Baranick held various leadership positions in the life sciences and diagnostics industries. He has a strong background in molecular diagnostics, having worked at companies such as Genomic Health and Roche Molecular Systems. At Genomic Health, Baranick played a key role in the development and launch of the Oncotype DX breast cancer test, which has become a widely used tool for guiding treatment decisions. His experience in bringing innovative diagnostic products to market has been invaluable to Exact Sciences as the company continues to expand its portfolio of cancer screening and diagnostic tests. Under Baranick's leadership, Exact Sciences has made significant strides in the field of precision oncology. The company's OncoExTra test, which provides comprehensive genomic profiling for advanced cancer patients, has been well-received by the medical community and is helping to guide more targeted treatment decisions. Baranick's strategic vision and commitment to improving patient outcomes have positioned Exact Sciences as a leader in the precision oncology space. As the company continues to invest in research and development, Baranick's role will be crucial in bringing new, innovative tests to market and improving the lives of cancer patients worldwide.